Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics is expected to have a positive financial outlook due to its successful initiation of a new long-term extension study for patients who completed the Phase 2b study of Halneuron for CINP treatment, expected to report results in Q3 of 2026. With no drugs currently approved for this indication in the US, a positive outcome could lead to significant market share and a clear regulatory path. Additionally, the company is in discussions for potential partnerships and its upcoming clinical program SP16 for CIPN, which could also drive positive outcomes and potential upside for the stock.

Bears say

Dogwood Therapeutics is a development-stage biopharmaceutical company with no current revenue and a projected net loss of $0.56 per share for 2026. Additionally, their cash on hand is only enough to fund operations until 2Q27, which could present challenges in the future. These factors suggest a negative outlook for their stock.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.